Tags Posts tagged with "$IMLFF"

$IMLFF

1 3943

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Disclaimer:
Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 3188

As you may or may not know I love Biotech companies as investment opportunities! The reason being is the fact they trade unlike any other companies out there and there are tangible milestones they can hit which when positive send the market into a buying frenzy. In the last year I’ve written about GWPH, ZYNE and CARA which are all Big Board (Nasdaq) companies in Forbes quite successfully and ahead of the market. Today I am writing about INMED, a Canadian based biotech company with board members from Eli Lilly, MIT and a Chief Medical officer formerly of GW Pharmaceuticals who will be the focus of this interview.

InMed has already distinguish themselves as a leading Cannabinoid Pharmaceutical Company. As one of very first biotech companies that entered the Cannabinoid research space, they are uniquely positioned capitalize on the anticipated growth of the cannabis-derived pharmaceutical market by creating not just therapies, but efficient scientific procedures to create those drugs and more importantly patent new methods in the process that are bankable & universal for other companies.

Today I am pleased to bring to the subscribers of Marijuanastocks.com an exclusive interview InMed’s Chief Medical Officer; Dr. Ado Muhammed, MD, DPM, MFPM.

He knows a few things about with cannabinoid based drugs as he is the former Assoc. Medical Director for GW Pharmaceuticals. GW Pharma and was part of the development team that developed Sativex, a cannabinoid based drug for MS that has been approved in over 15 countries worldwide.

Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.

I asked him to explain what InMed is doing and what separates them from Pack.

Q: What initially attracted you to join InMed an earlier stage biotech company involved in cannabis based Pharmaceuticals…an area you have a unique perspective on?

A: Initially it was InMed’s approach to drug discovery using their Bioinformatic program. This precision in the discovery process was a far more advanced approach than I had seen before in my career. The ability to discover compounds intelligently and efficiently to treat disease creates a significant industry advantage for InMed. Also, their drug delivery approach- avoiding systemic exposure through topical/local delivery I believe has a therapeutic advantage over oral delivery in terms of safety and efficacy.

Q: What differentiates InMed from other leading cannabinoid Biotech companies that you have seen?

In addition to the bioinformatics I see two other areas where InMed has an industry advantage. Firstly, using plant equivalent compounds versus others developing synthetic compounds is a clear advantage in my opinion. This will improve the safety profile of InMed’s therapies while providing the efficacious results expected in the treatments. Secondly, the ability to produce cannabinoids in the biosynthesis process

On the other spectrum InMed’s natural compound approach using specifically identified cannabinoids is also unique. This approach vs others using whole plant extracts and oils, is a more efficient method in terms of clinical development. Efficiency in time and cost

A: I understand you were at UBC yesterday getting an update from the team on the biosynthesis program. What essentially is this program and why is it so important for InMed and its shareholders?

Q: Essentially biosynthesis is a process that can manufacture cannabinoids out of a biologic system. This is a well-known system, as evidenced in the manufacturing of insulin, which is used by millions of diabetics daily. Again, I will point to efficiency and precision. Manufacturing cannabinoids in a controlled laboratory environment and eliminating the significant costs and variables associated with the current methods. This will have a major impact on both drug quality & costs. Also, the ability to produce all of the 90+ cannabinoids at a uniform cost open up InMed’s therapeutic potential and will secure our position as a world leader in cannabinoid prescription drug development.

Q: Fast forward 3 years…what are your top 3 indications

A: Of course, Epidermolysis Bullosa our lead therapy. We would expect to be in Phase 3 trials within 3 years and moving quickly to registration. Glaucoma we are targeting to have advanced to a stage where it can be partnered within the next 12 months. I also predict our advancement of other indications within the dermatology/orphan drug space, including the treatment of acute and chronic pain using a topical approach.

4.) Final Thoughts on InMed for our subscribers?

a. InMed has created a tremendous amount of value in a short period as evidenced by the assets in this company. InMed has the opportunity to become a world leader in cannabinoid based medicines and we are well on our way. The team we have assembled has both experience and capabilities to execute on this ambitious goal.

CONCLUSION:

The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020, and while we see the MJ licensed growers offering “medical” marijuana” The big winners in the Cannabis financial space will clearly be the Biotech’s like GWPH, ZYNE, CARA and Vancouver Biotech IMLFF. If you are not familiar with how the US cannabis industry is being tilted towards pharma companies I suggest you read this.

InMed (IMLFF) is a company I have known for a while, actually since I got involved in this space. When I first heard about them and met them two years ago I thought to myself “I wonder how far along they will be in two years?” Well 2 years later and they are positioning themselves in MY OPINION for Buyout or Biotech Glory. They are the frontrunner for Cannabis based Biotech in Canada, but more importantly…….

INMED is completely insulated by Federal, Country or State Law as it relates to Cannabis because at the end of the day they are science based nerds that happen to be mapping the Genome of pot!

1 11813

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

0 1117

InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS)

Pre-clinical studies of INM-750 to commence February, 2015Third Program Discovered Through InMed’s Proprietary Drug Design Platform

VANCOUVER, British Columbia, Feb. 3, 2015 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF) announced today that it has added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation and inflammation that are signature characteristics of EBS.

InMed anticipates commencing pre-clinical studies of INM-750 in February, 2015 with initial data expected by Q2 2015. The initiation of INM-750 signals InMed’s entry into the dermatological market and adds to the Company’s rapidly advancing pipeline of cannabis-based therapeutics, which includes CTI-805 for glaucoma and CT-091 for arthritis, both of which are expected to enter human clinical studies in 2015.

“We are pleased to continue the strategic diversification of our pipeline by adding a third therapy identified by our proprietary platform technology,” said Craig Schneider, President & CEO of InMed. “The discovery of INM-750 furthers our corporate strategy of developing therapies for diseases that may be approved for Orphan Drug Designation.”

Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer of InMed, stated, “EBS is a rare keratin mutation-related disease with no FDA approved treatment. The only options available to patients are wound care, pain management, and preventative bandaging. More severe forms of the disease lead to scarring, disfigurement, disability, and early death, usually before the age of 30.”

Craig Schneider concluded, “We are working rapidly to advance the development of INM-750 to address this significant unmet medical need.”

About Epidermolysis bullosa simplex (EBS)

Epidermolysis bullosa simplex (EBS) is Epidermolysis bullosa simplex (EBS) is one of the major forms of Epidermolysis bullosa a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and dermis, resulting in friction and skin fragility. Its severity ranges from mild to lethal. As of today there is no cure or effective treatment. Currently, wound care, pain management and preventative bandaging are the only options available for treatment. The more severe forms of the disease lead to scarring, disfigurement, disability and early death, usually before the age of 30.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visitwww.inmedpharma.com.

ON BEHALF OF THE BOARD

InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
Tel:  604.669.7207
Fax: 604.683.2506
info@inmedpharma.com / www.inmedpharma.com

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com
212-375-2664

Amy Wheeler (Media)
awheeler@tiberend.com
646-362-5750

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inmed-expands-pipeline-with-initiation-of-program-targeting-epidermolysis-bullosa-simplex-ebs-300029646.html

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements